Targeting NOX2 by prodigiosin to reduce metastasis warrants further investigation, considering reactive oxygen species (ROS) source, tumour cells’ susceptibility to ROS toxicity, cancer progression stage, and effector cells’ sensitivity to ROS‐induced immunosuppression. The gene discussed is CYBB; the disease is neoplasm.